

10/08/00



Jc196 U.S. PTO

08-09-01

S&Box

A

Place sign (+) inside this box →

SUBSTITUTE for PTO/SB/05 (08/00) Utility Patent Application Transmittal
Approved for use through 10/31/2002 OMB 0651-0032
U S Patent and Trademark Office U S DEPARTMENT OF COMMERCEUTILITY
PATENT APPLICATION
TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No

20183YCA

First Inventor or Application Identifier

Dong-Mei Feng

Title

CONJUGATES USEFUL IN THE TREATMENT OF
PROSTATE CANCER

Express Mail Label No

EL523905034US

10/08/00 U.S. PTO

09/924824



08/08/01

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

1. ☒ Fee Transmittal Form
(Submit an original, and a duplicate for fee processing)
2. ☒ Specification [Total Pages]
3. ☐ Drawing(s) (35 USC 113) [Total Sheets]
[Total Pages]
4. Oath or Declaration
- a. ☐ Newly executed (original or copy)
- b. ☒ Copy from a prior application (37 CFR 1.63(d))
(for continuation/divisional with Box 14 completed)
- i. ☐ DELETION OF INVENTOR(S)
Signed statement attached deleting
inventor(s) named in the prior
application, see 37 CFR 1.63(d)(2)
and 1.33 (b).
5. ☐ Application Data Sheet. See 37 CFR 1.76

ADDRESS TO:

Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

6. Nucleotide and/or Amino Acid Sequence Submission
(if applicable, all necessary)

- a. ☒ Computer Readable Form
- b. ☒ Paper Copy (identical to computer copy)
- c. ☐ Statements verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

7. ☐ Assignment papers (cover sheet & document(s))
8. ☐ 37 CFR 3.73(b) Statement (when there is an assignee) ☐ Power of Attorney
9. ☐ Information Disclosure Statement (IDS)/PTO-1449 ☐ Copies of IDS Citations
10. ☐ Preliminary Amendment
11. ☒ Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
12. ☐ Certified Copy of Priority Document(s)
(if foreign priority is claimed)
13. ☐ Other: _____

14. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76.

☒ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No 09:262,538
Prior application information. Examiner _____ Group/Art Unit: _____

For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 4b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference.

15. CORRESPONDENCE ADDRESS

☒ Customer Number or Bar Code
Label

Customer No. 000210
(Insert Customer No. or Attach bar code here)

NAME	David A. Muthard				
ADDRESS	Merck & Co, Inc, P. O. Box 2000 - Patent Dept., RY60-30				
CITY	Rahway	STATE	NJ	ZIP CODE	07065-0907
COUNTRY	USA	TELEPHONE	732-594- 3903	FAX	732-594-4720

Name	David A Muthard	Registration No (Attorney/Agent)	35,297
Signature		Date	8/8/01

EXPRESS MAIL CERTIFICATE

DATE OF DEPOSIT August 8, 2001

EXPRESS MAIL NO. EL523905034US

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE
UNITED STATES POSTAL SERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRESSEE"
ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO ASSISTANT COMMISSIONER
FOR PATENTS, BOX PATENT APPLICATION, WASHINGTON, D.C. 20231.

MAILED BY

DATE August 8, 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Assistant Commissioner for Patents
Washington, D.C. 20231

Prior Application:

Examiner	F. Moezie
Art Unit	1653

Sir: This is a request for filing a ☒ Continuation ☐ Divisional

application, under 37 C.F.R. 1.53(b), of pending application Serial No. 09/262,538 filed on

3/4/1999 (DATE) of Dong-Mei Feng (INVENTOR)

for CONJUGATES USEFUL IN THE TREATMENT OF PROSTATE CANCER
 (TITLE OF INVENTION)

1. The enclosed comprises a copy of prior application Serial No. 09/262,538, as filed on 3/4/1999. The entire disclosure of this prior application is hereby incorporated by reference.

2. The filing fee is calculated below:

CLAIMS AS FILED IN THE PRIOR APPLICATION, LESS ANY CLAIMS CANCELED BY AMENDMENT BELOW

FOR	NUMBER FILED	NUMBER EXTRA	RATE	FEE
Total Claims	25	5	\$18	\$90
Independent Claims	4	1	\$80	\$80
*Multiple Dependent Claims			\$270	
Basic Fee (minimum amount required)				\$710
* Add this fee if application contains any multiple dependent claims, regardless of number.				\$880
				Total Fee

3. The Assistant Commissioner is hereby authorized to charge any fees which may be required or to credit any overpayment to Account No. 13-2755.

4. ☒ Amend the specification by inserting before the first line the sentence:

-- This is a ☒ continuation, ☐ division of application Serial No. 09/262,538,
 filed 3/4/1999

5. ☐ Cancel in this application original claims:

6. ☐ Preliminary amendment enclosed.

7. ☐ Information Disclosure Statement/PTO-1449 enclosed.

8a. ☐ Transfer the drawings from the prior application to this application and abandon said prior application as of the filing date accorded this application. A duplicate copy of this sheet is enclosed for filing in the prior application file.

8b. ☐ New formal drawings are enclosed.

9a. ☐ Priority of application Serial No. _____, filed _____,
 in _____ (COUNTRY) is claimed under 35 U.S.C. 119.

9b. ☐ The certified copy of the priority application has been filed in prior application Serial No. _____,
 filed _____

10. ☐ The prior application is assigned to _____

11. ☒ The undersigned attorney or agent has:

a. ☒ Power in the prior application as originally filed.

b. ☐ Associate power, copy enclosed.

Respectfully,

By: David A. Muthard

Attorney _____ for Applicant(s)

Registration No. 35,297

Telephone: (732) 594-3903

Address: Merck & Co., Inc.
Patent Department
P.O. Box 2000 - RY60-30
Rahway, N.J. 07065-0907

Date: 8/8/01

EXPRESS MAIL CERTIFICATE

DATE OF DEPOSIT 8/8/01

EXPRESS MAIL NO. EL523905034US

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRESSEE" ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231.

MAILED BY [Signature] DATE 8/8/01

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Dong-Mei Feng	
Serial No.:	To Be Assigned	Case No.: 20183YCA
Filed:	August 8, 2001	
For:	CONJUGATES USEFUL IN THE TREATMENT OF PROSTATE CANCER	

Art Unit:
To Be Determined

Examiner:
To Be Determined

Assistant Commissioner for Patents
Washington, D.C. 20231

LETTER

Sir:

In compliance with 37 C.F.R. 1.821(f) of the Rules of Practice In Patent Cases:
Application Disclosures Containing Nucleotide and/or Amino Acid Sequences, the signature page and
following statement are being submitted herewith.

I hereby state that the content of the paper and computer readable copies of the Sequence
Listing, submitted in accordance with 37 C.F.R. 1.821(c) and (e), respectively, are the same.

The enclosed diskette contains the Sequence Listing for case number 20183Y.

Respectfully submitted,

By: 

David A. Muthard
Registration No. 35,297
Attorney for Applicants

Merck & Co., Inc.
P.O. Box 2000 - RY 60-30
Rahway, New Jersey 07065-0907
Telephone No. (732) 594-3903

Date: August 8, 2001

Express Mail Certificate

Date of Deposit August 8, 2001
Express Mail No. EL523905034US

I hereby certify that this correspondence is being deposited with the
United States Postal Service as Express Mail "Post Office to Addressee"
before 5 p.m. on the above date in an envelope addressed to
Assistant Commissioner for Patents, Washington, D.C. 20231

Mailed By 

Date August 8, 2001